---
figid: PMC12113536__metabolites-15-00304-g001
figtitle: Aberrant pathways induced by SMARCB1 deficiency and corresponding therapeutic
  targets
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12113536
filename: metabolites-15-00304-g001.jpg
figlink: /pmc/articles/PMC12113536/figure/F1/
number: F1
caption: Aberrant pathways induced by SMARCB1 deficiency and corresponding therapeutic
  targets. ‘PRC2’ denotes polycomb repressive complex 2, ‘AURKA’ Aurora Kinase A,
  ‘RTK’ receptor tyrosine kinase, ‘BRD9’ bromodomain-containing protein 9, ‘GLTSCR1’
  glioma tumour suppressor candidate region gene 1, ‘Rb’ retinoblastoma, ‘CDK4/6’
  cyclin-dependent kinase 4/6, ‘PD-1’ programmed cell death protein 1, ‘CTLA-4’ cytotoxic
  T-lymphocyte–associated protein 4; SAM, S-adenosyl methionine, ‘PI3K’ phosphoinositide
  3-kinase; ‘Akt’ protein kinase B; ‘mTOR’ mammalian target of rapamycin, and ‘HMGCR’
  HMG-CoA reductase. Solid black arrows indicate activation or promotion of a protein
  or pathway. Solid bars with red cross indicate loss of inhibition. Red bars denote
  inhibition by corresponding drug or therapy. The symbol “P” in the yellow circle
  represents phosphorylation. Figure created with BioRender.com
papertitle: 'SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid
  Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and
  Ongoing Clinical Trials'
reftext: Abdul L. Shakerdi, et al. Metabolites. 2025 May;15(5).
year: '2025'
doi: 10.3390/metabo15050304
journal_title: Metabolites
journal_nlm_ta: Metabolites
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: rhabdoid tumours | SMARCB1 deficiency | hallmarks of cancer | energy metabolism
  | targeted therapy
automl_pathway: 0.9295725
figid_alias: PMC12113536__F1
figtype: Figure
redirect_from: /figures/PMC12113536__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12113536__metabolites-15-00304-g001.html
  '@type': Dataset
  description: Aberrant pathways induced by SMARCB1 deficiency and corresponding therapeutic
    targets. ‘PRC2’ denotes polycomb repressive complex 2, ‘AURKA’ Aurora Kinase A,
    ‘RTK’ receptor tyrosine kinase, ‘BRD9’ bromodomain-containing protein 9, ‘GLTSCR1’
    glioma tumour suppressor candidate region gene 1, ‘Rb’ retinoblastoma, ‘CDK4/6’
    cyclin-dependent kinase 4/6, ‘PD-1’ programmed cell death protein 1, ‘CTLA-4’
    cytotoxic T-lymphocyte–associated protein 4; SAM, S-adenosyl methionine, ‘PI3K’
    phosphoinositide 3-kinase; ‘Akt’ protein kinase B; ‘mTOR’ mammalian target of
    rapamycin, and ‘HMGCR’ HMG-CoA reductase. Solid black arrows indicate activation
    or promotion of a protein or pathway. Solid bars with red cross indicate loss
    of inhibition. Red bars denote inhibition by corresponding drug or therapy. The
    symbol “P” in the yellow circle represents phosphorylation. Figure created with
    BioRender.com
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AURKA
  - MYC
  - HMGCR
  - ME3
  - PCDHGA5
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - EED
  - EZH1
  - EZH2
  - SUZ12
  - CDKN2A
  - H3P10
  - CARTPT
  - CDK4
  - CDK6
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - SMARCB1
  - SMARCA1
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - BRD9
  - CTLA4
  - BICRA
  - Alisertib
  - SAM
  - Palbociclib
  - Simvastatin
  - Ponatinib
---
